Filing Flows › PTC Therapeutics (PTCT) › Guidance history
PTC Therapeutics (PTCT) guidance history: what it guided and what it reported
PTC Therapeutics gave guidance in 12 earnings releases on file since Aug 8, 2024. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +4.1% against the guided midpoint. Its releases raised guidance 4 times and lowered it 0 times.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $850M–$950M (Jul 30, 2026) → raised $1.3B–$1.3B (Oct 29, 2026) | — | to be reported | — |
| FY2024 | $700M–$750M (Aug 8, 2024) → raised $750M–$800M (Nov 7, 2024) | $807M | above the range | +4.1% |
The latest quarter
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
Questions
Does PTC Therapeutics beat its guidance?
PTC Therapeutics gave guidance in 12 earnings releases on file since Aug 8, 2024. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +4.1% against the guided midpoint.
How often does PTC Therapeutics raise guidance?
Its earnings releases raised guidance 4 times and lowered it 0 times since Aug 8, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.